Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.63 |
| ▸ | GAA | P10253 | 2/20 | 0.63 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.63 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | BCHE | P06276 | 1/20 | 0.48 |
| ▸ | ACHE | P22303 | 1/20 | 0.48 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.47 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.47 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.46 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3039189 | 0.95 | ALDH1A1 (0.59) | ALDH1A1GAAALOX15MAPK1SMN1; SMN2 | |
| SCHEMBL10897950 | 0.85 | ALDH1A1 (0.65) | ALDH1A1GAAALOX15MAPK1SMN1; SMN2 | |
| SCHEMBL11638744 | 0.84 | ALDH1A1 (0.51) | ALDH1A1GAAALOX15MAPK1SMN1; SMN2 | |
| SCHEMBL11694180 | 0.84 | ALDH1A1 (0.63) | ALDH1A1GAAALOX15MAPK1SMN1; SMN2 | |
| SCHEMBL7934938 | 0.84 | ALDH1A1 (0.63) | ALDH1A1GAAALOX15MAPK1SMN1; SMN2 | |
| SCHEMBL21765844 | 0.82 | POLB (0.56) | ALDH1A1GAASMN1; SMN2MAPTMEN1 | |
| SCHEMBL9850070 | 0.82 | ALDH1A1 (0.58) | ALDH1A1GAAALOX15MAPK1SMN1; SMN2 | |
| SCHEMBL11689447 | 0.81 | ALDH1A1 (0.68) | ALDH1A1GAAALOX15MAPK1SMN1; SMN2 | |
| SCHEMBL9060872 | 0.81 | HPGD (0.68) | ALDH1A1GAAALOX15MAPK1SMN1; SMN2 | |
| SCHEMBL3769612 | 0.81 | ALDH1A1 (0.72) | ALDH1A1GAAALOX15MAPK1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7645784-B2 | Benzimidazole derivatives | ASTRAZENECA AB (SE) | 2010-01-12 | — | — | US | disclosed |
| EP-2042490-A2 | Benzimidazole derivatives as vanilloid receptor antagonists | AstraZeneca AB (SE) | 2009-04-01 | — | — | EP | disclosed |
| EP-1626964-B1 | NEW BENZIMIDAZOLE DERIVATIVES | ASTRAZENECA AB (SE) | 2009-01-21 | — | — | EP | disclosed |
| CN-101328150-A | New benzimidazole derivatives | ASTRAZENECA AB (SE) | 2008-12-24 | — | — | CN | disclosed |
| CN-100413849-C | Benzimidazole derivatives | ASTRAZENECA AB (SE) | 2008-08-27 | — | — | CN | disclosed |
| US-20060287377-A1 | New benzimidazole derivatives | ASTRAZENECA AB (SE) | 2006-12-21 | — | — | US | disclosed |
| CN-1784387-A | Novel benzimidazole derivatives | ASTRAZENECA AB (SE) | 2006-06-07 | — | — | CN | disclosed |
| EP-1626964-A2 | NEW BENZIMIDAZOLE DERIVATIVES | AstraZeneca AB (SE) | 2006-02-22 | — | — | EP | disclosed |
| WO-2004100865-A2 | NEW BENZIMIDAZOLE DERIVATIVES | ASTRAZENECA AB (SE) | 2004-11-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060287377-A1 | New benzimidazole derivatives | CYP2C9, CDK9, CCNI | ALDH1A1 668/4885GAA 1172/4885ALOX15 4666/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.